SEARCH:   Advanced

Blood, 15 June 2005, Vol. 105, No. 12, pp. 4807-4812. Prepublished online as a Blood First Edition Paper on March 3, 2005; DOI 10.1182/blood-2004-11-4394. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-11-4394v1 105/12/4807    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Grabowski, P. Articles by Roos, G. Search for Related Content PubMed PubMed Citation Articles by Grabowski, P. Articles by Roos, G. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status Pawel Grabowski, Magnus Hultdin, Karin Karlsson, Gerard Tobin, Anna Åleskog, Ulf Thunberg, Anna Laurell, Christer Sundström, Richard Rosenquist, and Göran Roos From the Department of Medical Biosciences, Pathology, Umeå University, Umeå; Department of Medicine, Linköping University, Linköping; and Departments of Genetics and Pathology, Medical Sciences and Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden. B-cell chronic lymphocytic leukemia (CLL) consists of 2 prognostic entities where cases with mutated immunoglobulin VH genes have better outcome than unmutated cases. VH-mutated CLLs display longer telomeres compared with unmutated cases and telomere length has been indicated to predict outcome, although the prognostic value of telomere length has not been fully established in CLL. We analyzed telomere length, VH gene mutation status, and clinical parameters in a large series of CLL. Telomere length was assessed by quantitative polymerase chain reaction (PCR), giving a very good correlation to telomere length estimated by Southern blotting (P < .001). The prognostic information given by mutation status (n = 282) and telomere length (n = 246) was significant (P < .001, respectively). Telomere length was a prognostic factor for stage A (P = .021) and stage B/C (P = .018) patients, whereas mutation status predicted outcome only in stage A patients (P < .001). Furthermore, mutated CLLs were subdivided by telomere length into 2 groups with different prognoses (P = .003), a subdivision not seen for unmutated cases (P = .232). Interestingly, the VH-mutated group with short telomeres had an overall survival close to that of the unmutated cases. Thus, by combining VH mutation status and telomere length, an improved subclassification of CLL was achieved identifying previously unrecognized patient groups with different outcomes. (Blood. 2005;105:4807-4812) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Roos, R. Rosenquist, and S. Stilgenbauer Response: Or both? Blood, June 15, 2008; 111(12): 5756 - 5757. [Full Text] [PDF] U. Svenson, K. Nordfjall, B. Stegmayr, J. Manjer, P. Nilsson, B. Tavelin, R. Henriksson, P. Lenner, and G. Roos Breast Cancer Survival Is Associated with Telomere Length in Peripheral Blood Cells Cancer Res., May 15, 2008; 68(10): 3618 - 3623. [Abstract] [Full Text] [PDF] G. Roos, A. Krober, P. Grabowski, D. Kienle, A. Buhler, H. Dohner, R. Rosenquist, and S. Stilgenbauer Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia Blood, February 15, 2008; 111(4): 2246 - 2252. [Abstract] [Full Text] [PDF] M. Bellon and C. Nicot Regulation of Telomerase and Telomeres: Human Tumor Viruses Take Control J Natl Cancer Inst, January 16, 2008; 100(2): 98 - 108. [Abstract] [Full Text] [PDF] R. N. Damle, S. Temburni, C. Calissano, S. Yancopoulos, T. Banapour, C. Sison, S. L. Allen, K. R. Rai, and N. Chiorazzi CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells Blood, November 1, 2007; 110(9): 3352 - 3359. [Abstract] [Full Text] [PDF] S. Avigad, I. Naumov, A. Ohali, M. Jeison, G. H. Berco, J. Mardoukh, B. Stark, S. Ash, I. J. Cohen, I. Meller, et al. Short Telomeres: A Novel Potential Predictor of Relapse in Ewing Sarcoma Clin. Cancer Res., October 1, 2007; 13(19): 5777 - 5783. [Abstract] [Full Text] [PDF] P. van der Harst, G. van der Steege, R. A. de Boer, A. A. Voors, A. S. Hall, M. J. Mulder, W. H. van Gilst, D. J. van Veldhuisen, and on behalf of the MERIT-HF Study Group Telomere Length of Circulating Leukocytes Is Decreased in Patients With Chronic Heart Failure J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1459 - 1464. [Abstract] [Full Text] [PDF] D. J. Kurz, B. Kloeckener-Gruissem, A. Akhmedov, F. R. Eberli, I. Buhler, W. Berger, O. Bertel, and T. F. Luscher Degenerative Aortic Valve Stenosis, but not Coronary Disease, Is Associated With Shorter Telomere Length in the Elderly Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): e114 - e117. [Abstract] [Full Text] [PDF] K. Nordfjall, A. Larefalk, P. Lindgren, D. Holmberg, and G. Roos Telomere length and heredity: Indications of paternal inheritance PNAS, November 8, 2005; 102(45): 16374 - 16378. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020